A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants

Abstract This study aimed to evaluate the durability of the immunogenicity of MVA85A beyond infancy. Participants in an immunogenicity study of MVA85A administered at age of 4 months had additional evaluation 14 months after initial vaccination for IFN-γ ELISPOT responses to Ag85A peptide and ESAT6/...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-08, Vol.30 (38), p.5591-5594
Main Authors: Odutola, A.A, Owolabi, O.A, Owiafe, P.K, McShane, H, Ota, M.O.C
Format: Article
Language:English
Subjects:
Acyltransferases - immunology
Africa
Africans
Age
Allergy and Immunology
anthropometric measurements
Antigens
Antigens, Bacterial - immunology
Bacterial Proteins - immunology
Blood
children
durability
Enzyme-Linked Immunospot Assay
ESAT6/CFP10
Female
Humans
Immune response
Immunogenicity
Immunologic Memory
infancy
Infant
infants
Infections
interferon-gamma
Male
MVA85A
Mycobacterium tuberculosis
PPD-T
TB vaccine, Durability of immunity
Time Factors
tuberculin
Tuberculin skin test
Tuberculin Test
Tuberculosis
Tuberculosis Vaccines - administration & dosage
Tuberculosis Vaccines - immunology
vaccination
Vaccination - methods
Vaccines
Vaccines, DNA
Viral Vaccines - administration & dosage
Viral Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This study aimed to evaluate the durability of the immunogenicity of MVA85A beyond infancy. Participants in an immunogenicity study of MVA85A administered at age of 4 months had additional evaluation 14 months after initial vaccination for IFN-γ ELISPOT responses to Ag85A peptide and ESAT6/CFP-10 and tuberculin skin test (TST). 112 children participated in this study. The anthropometry, biochemical and haematological safety profile were similar between the MVA85A recipients and controls. MVA85A recipients still had significantly higher immune responses to Ag85A compared to the controls. The majority of these children had negative responses to the TST as well as the ESAT6/CFP-10 antigens. In summary, MVA85A-vaccinated children had a persistently higher Ag85A immune response 14 months following vaccination than controls. All the children had negligible evidence of latent infection with M. tuberculosis ( Mtb ), suggesting that deploying a prophylactic vaccine against Mtb infection at this age could still be effective in this setting.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.06.054